Pre- and postexposure prophylaxis of Ebola virus infection in an animal model by passive transfer of a neutralizing human antibody.
A neutralizing human monoclonal antibody, KZ52, protects guinea pigs from lethal Ebola Zaire virus challenge. Administration before or up to 1 h after challenge resulted in dose-dependent protection by the antibody. Interestingly, some antibody-treated animals survived despite developing high-level viremia, suggesting that the mechanism of protection by KZ52 may extend beyond reduction of viremia by virus neutralization. KZ52 is a promising candidate for immunoprophylaxis of Ebola virus infection.
Parren
Paul W H I
PW
Department of Immunology, The Scripps Research Institute, La Jolla, California 92037, USA.
Geisbert
Tom W
TW
Maruyama
Toshiaki
T
Jahrling
Peter B
PB
Burton
Dennis R
DR
D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000276:immunology / Q000627:therapeutic use; D000914:Antibodies, Viral / Q000008:administration & dosage / Q000276:immunology / Q000627:therapeutic use; D004195:Disease Models, Animal; D029043:Ebolavirus / Q000276:immunology* / Q000472:pathogenicity; D006168:Guinea Pigs; D019142:Hemorrhagic Fever, Ebola / Q000276:immunology / Q000517:prevention & control* / Q000628:therapy; D006801:Humans; D007116:Immunization, Passive; D009500:Neutralization Tests
D000911:Antibodies, Monoclonal; D000914:Antibodies, Viral